Form 4 for IGC IGC Pharma, Inc.
Accepted 2026-04-06 16:01:39 ET · period of report 2026-04-01 · accession 0001185185-26-001283 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-04-06 16:01 | 2026-04-01 | IGC | GRIMALDI CLAUDIA | PFO, Dir | M - OptEx | $0.151 | +238.5K | 1.37M | +21% | +$36.0K |
| DM | 2026-04-06 16:01 | 2026-04-01 | IGC | GRIMALDI CLAUDIA | PFO, Dir | M - OptEx | $0.00 | -238.5K | 221.5K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 100,000 | $0.00 | 1,234,252 | D | — | — | (F1) On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024. |
| 2 | Common | Common Stock | 2026-04-01 | M | A | 138,462 | $0.26 | 1,372,714 | D | — | — | (F1) On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024. |
| 3 | Derivative | Restricted Stock Units | 2026-04-01 | M | D | 100,000 | $0.00 | 0 | D | — · — to — | 100,000 Common Stock | (F3) Each restricted stock unit represents a right to receive one share of IGC common stock. (F1) On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024. (F1) On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024. (F1) On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024. |
| 4 | Derivative | Options | 2026-04-01 | M | D | 138,462 | $0.00 | 221,538 | D | $0.26 · — to 2034-03-12 | 138,462 Common Stock | (F2) On March 13, 2024, the Reporting Person was granted Options subject to vesting equally over three years starting in March 2025. The exercise price is $0.26. (F2) On March 13, 2024, the Reporting Person was granted Options subject to vesting equally over three years starting in March 2025. The exercise price is $0.26. |